Back to top

Bull of the Day

Zacks Equity Research

Osiris Therapeutics (OSIR)

OSIR

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Osiris Therapeutics (OSIR) reported third quarter earnings of $0.14 per share, well above the Zacks Consensus Estimate of a profit of $0.04 and the year-ago loss of $0.21. Results were mainly driven by lower operating expenses. Revenues of $10.8 million were just above the Zacks Consensus Estimate of $10 million.

Lead pipeline candidate Prochymal has the potential to be a sort of a wonder drug for various inflammatory or tissue damage indications. Prochymal could be a billion-dollar blockbuster product if all development goes well. Meanwhile, the sales opportunity for Chondrogen, the company's second pipeline candidate, could also be significant.

We view the company's collaboration agreement with large-cap biotech Genzyme as a positive. We believe the current share price represents an attractive entry point and maintain our Outperform rating on the stock. Based on third quarter results, we have increased our 2010 and 2011 earnings estimates.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%